Home Cart Sign in  
Chemical Structure| 1883423-59-3 Chemical Structure| 1883423-59-3

Structure of MSC2530818
CAS No.: 1883423-59-3

Chemical Structure| 1883423-59-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MSC2530818 is a Potent, Selective, and Orally Bioavailable CDK8 inhibitor with CDK8 IC50 = 2.6 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MSC2530818

CAS No. :1883423-59-3
Formula : C18H17ClN4O
M.W : 340.81
SMILES Code : O=C(N1[C@H](C2=CC=C(Cl)C=C2)CCC1)C3=CN=C(NN=C4C)C4=C3
MDL No. :MFCD31382190
InChI Key :ODRITQGYYWHQGM-INIZCTEOSA-N
Pubchem ID :118879529

Safety of MSC2530818

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of MSC2530818

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK8

    CDK8, IC50:2.6 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 cells 30 nM 3 hours To assess the stability of CDK8/19 inhibition, results showed that MSC2530818's inhibition was less stable than dCA PMC6912361
Human foreskin fibroblasts (HFFs) 1.21 ± 0.77 nM 7 days Evaluation of the antiviral activity of MSC2530818 against HCMV AD169-GFP replication, showing nanomolar-level inhibition. PMC11435438
U373 cells 18.47 ± 11.20 nM 7 days Evaluation of the antiviral activity of MSC2530818 against HCMV AD169-GFP replication in U373 cells, showing nanomolar-level inhibition. PMC11435438
pancreatic progenitors 50 nM 7 days To induce differentiation of pancreatic progenitors into pancreatic duct-like organoids (PDLOs) PMC7611572
Pancreatic duct-like organoids 50 × 10^-9 M 14 days Used to investigate pancreatic disease onset and carcinogenesis, and to promote the differentiation of pancreatic duct-like organoids. PMC11468201
Pancreatic duct-like organoids (PDLOs) 0.05 μM 17 days MSC2530818 at 0.05 μM increased CFTR expression, but higher concentrations disrupted organoid morphology PMC8461636
HEK293T cells 1 μM 24 hours MSC2530818 significantly inhibited IFN-ɑ-induced STAT1 Ser727 phosphorylation and LATS1-mediated up-regulation of STAT1 Ser727 phosphorylation. PMC8993116

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish Zebrafish embryos Aqueous solution 8 mg/kg Twice a week for 18 weeks To evaluate the in vivo toxicity of MSC2530818, results showed significant toxicity in zebrafish embryos PMC6912361
Mice C57Bl/6 male mice Oral 0.5 mg/kg or 1.0 mg/kg every 2 days for 14 days Evaluate the pharmacokinetic properties of MSC2530818, showing a Cmax of 1.04 μM after oral dosing and low clearance. PMC8591729
Mice NOD scid gamma (NSG) mice Orthotopic transplantation into the pancreas 10 mg/kg three times a week for 6 consecutive weeks Transplanted PDLOs formed complex duct-like structures in vivo and expressed duct-specific markers PMC8461636

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.93mL

0.59mL

0.29mL

14.67mL

2.93mL

1.47mL

29.34mL

5.87mL

2.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories